Objective Cell-based therapy can improve cardiac function but is limited by the low cell retention and survival within ischaemic tissues. Injectable cardiac tissue engineering aims to support cell-based therapies and enhance their efficacy for cardiac diseases. Our research is devoted to studying the usefulness of the combination of fibrin glue (as scaffold) and adipose-derived stem cells (ADSCs) to treat myocardial infarction.
Methods The rat ADSCs were isolated from subcutaneous adipose tissues. The surface phenotype of these cells was analysed by flow cytometry. Fibrin glue was then co-injected with ADSCs into the left ventricular wall of rat infarction models. The structure and functional consequences of transplantation were determined by detailed histological analysis and echocardiography.
Results Most cultured ADSCs expressed CD105 and CD90, and negative for CD34 and CD45. After injection, both the 24h-cell retention and 4-week graft size were significantly higher and larger in the Fibrin+ ADSCs group than those of the ADSCs group alone (p<0.01). The ADSCs could differentiate into cardiomyocyte-like, endothelial and vascular smooth muscle cells in vivo. The heart function improved significantly in the Fibrin+ADSCs group compared to that of the ADSCs group 4 weeks after transplantation (p<0.01). In addition, the arteriole densities within the infarcted area improved significantly in the Fibrin+ADSCs group compared to those in the ADSCs group, 4 weeks after transplantation (p<0.01).
Conclusions The ADSCs with fibrin glue has the therapeutic potential to improve the function of infarcted hearts. The method of in situ injectable tissue engineering combining fibrin glue with ADSCs is promising clinically.
- Preservation of cardiac function
- adipose-derived stem cells